Skip to main content
. Author manuscript; available in PMC: 2020 Jan 4.
Published in final edited form as: Curr Cancer Drug Targets. 2019;19(10):838–851. doi: 10.2174/1568009619666190325144636

Table 1:

NSCLC cell lines used in this study.

ATCC® No. Name Histology Tumor Source Mutant Gene
CCL75™ WI38 Normal Lung
CCL-185™ A549 Carcinoma explant culture of lung carcinomatous tissue KRAS - G12S (c.34G > A)
CRL-5803™ NCI-H1299 Large cell carcinoma metastasis, lymph node NRAS - Q61K (c.181C > A)
CRL-5875™ NCI-H1563 Non-small-cell lung carcinoma (NSCLC) primary CDKN2A
HTB-177™ NCI-H460  lung: pleural effusion KRAS - Q61H (c.183A > T)
HTB-183™ NCI-H661 Large cell carcinoma metastasis, lymph node CDKN2A
SMARCA4
TP53
CRL-5877™ NCI-H1573 Adenocarcinoma metastasis, soft tissue KRAS
CRL-5908™ NCI-H1975 Non-small-cell lung carcinoma (NSCLC) primary CDKN2A, EGFR - L858R/T790M (c.2369C > T)